ABSTRACT
The development of excipient materials for use in drug formulations represents a growing area of interest (and of invested time and cost) for pharmaceutical companies. Such development has been fuelled by the increasing need for more sophisticated excipients and/or new uses for established ones. This entry examines the safety evaluation process for excipients from a preclinical perspective and shows that the role of the toxicologist is indeed a challenging one.
